Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES ROGERS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1073619078
CMS profile
93456
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,567.18

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $1,500.00 1
Food and Beverage $67.18 4

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES ROGERS

NPI 1073619078 · CMS profile ID 93456

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073619078?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES ROGERS, NPI 1073619078, CMS profile ID 93456. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073619078?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHARLES ROGERS, NPI 1073619078, CMS profile ID 93456. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073619078?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHARLES ROGERS, NPI 1073619078, CMS profile ID 93456, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1073619078?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $1,567.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Hologic Sales and Service, LLC $14.9712/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182520689 CMS
Sumitomo Pharma America, Inc. $16.8311/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176712355 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.6507/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225748607 CMS
INTUITIVE SURGICAL, INC. $1,500.0005/06/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1236524850 CMS
Hologic Sales and Service, LLC $15.7302/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182520498 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $211.89 14
PY2020 $147.77 11
PY2021 $367.33 25
PY2022 $191.74 15
PY2023 $50.47 4
PY2024 $23.32 1
PY2025 $1,567.18 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $64,452.88 14
PY2022 Principal investigator $698,324.95 119
PY2021 Principal investigator $841,564.46 110
PY2020 Principal investigator $209,720.80 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

110 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,994.96 12/29/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832552739
Principal investigator 1 PFIZER INC. $894.96 12/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832557889
Principal investigator 1 PFIZER INC. $4,016.10 12/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832557897
Principal investigator 1 GlaxoSmithKline, LLC. $2,150.28 12/21/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538669
Principal investigator 1 GlaxoSmithKline, LLC. $965.25 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809493831
Principal investigator 1 GlaxoSmithKline, LLC. $3,198.69 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809493851
Principal investigator 1 GlaxoSmithKline, LLC. $2,941.29 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809498245
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809498377
Principal investigator 1 GlaxoSmithKline, LLC. $2,246.31 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809498383
Principal investigator 1 GlaxoSmithKline, LLC. $1,042.47 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809517621
Principal investigator 1 GlaxoSmithKline, LLC. $2,509.65 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809519419
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809519437
Principal investigator 1 GlaxoSmithKline, LLC. $2,239.38 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538687
Principal investigator 1 GlaxoSmithKline, LLC. $1,132.56 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538699
Principal investigator 1 GlaxoSmithKline, LLC. $2,805.66 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538705
Principal investigator 1 GlaxoSmithKline, LLC. $5,632.11 12/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538735
Principal investigator 1 PFIZER INC. $21,925.86 12/07/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832563731
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809498263
Principal investigator 1 GlaxoSmithKline, LLC. $1,976.04 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538693
Principal investigator 1 GlaxoSmithKline, LLC. $3,597.66 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538723
Principal investigator 1 GlaxoSmithKline, LLC. $2,053.26 11/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538729
Principal investigator 1 PFIZER INC. $93,377.13 11/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832880819
Principal investigator 1 GlaxoSmithKline, LLC. $5,798.43 11/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494853
Principal investigator 1 GlaxoSmithKline, LLC. $12,292.83 11/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809498269
Principal investigator 1 PFIZER INC. $39,790.74 11/05/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832903931
Principal investigator 1 GlaxoSmithKline, LLC. $6,384.51 11/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490013
Principal investigator 1 GlaxoSmithKline, LLC. $939.51 11/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809525049
Principal investigator 1 GlaxoSmithKline, LLC. $1,596.87 11/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809493193
Principal investigator 1 GlaxoSmithKline, LLC. $1,203.84 11/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809516429
Principal investigator 1 GlaxoSmithKline, LLC. $1,075.14 11/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538675
Principal investigator 1 GlaxoSmithKline, LLC. $1,673.10 10/25/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809516423
Principal investigator 1 GlaxoSmithKline, LLC. $2,972.97 10/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809505591
Principal investigator 1 GlaxoSmithKline, LLC. $1,744.38 10/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809519323
Principal investigator 1 GlaxoSmithKline, LLC. $290.07 10/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809519573
Principal investigator 1 GlaxoSmithKline, LLC. $1,718.64 10/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809543403
Principal investigator 1 PFIZER INC. $1,463.88 10/19/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832673301
Principal investigator 1 GlaxoSmithKline, LLC. $1,203.84 10/13/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809495503
Principal investigator 1 GlaxoSmithKline, LLC. $1,261.26 10/13/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809498257
Principal investigator 1 GlaxoSmithKline, LLC. $2,472.03 10/13/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809519431
Principal investigator 1 PFIZER INC. $29,197.41 10/08/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832841619
Principal investigator 1 GlaxoSmithKline, LLC. $9,286.20 10/06/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809538681
Principal investigator 1 GlaxoSmithKline, LLC. $1,976.04 09/22/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809503795
Principal investigator 1 GlaxoSmithKline, LLC. $2,072.07 09/22/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809524705
Principal investigator 1 GlaxoSmithKline, LLC. $4,112.46 09/22/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809540187
Principal investigator 1 GlaxoSmithKline, LLC. $2,729.43 09/22/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809540933
Principal investigator 1 PFIZER INC. $32,792.10 09/22/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832876083
Principal investigator 1 PFIZER INC. $1,444.08 09/21/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832672715
Principal investigator 1 GlaxoSmithKline, LLC. $1,673.10 09/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809503637
Principal investigator 1 GlaxoSmithKline, LLC. $1,203.84 09/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809503661
Principal investigator 1 GlaxoSmithKline, LLC. $1,378.08 09/15/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809524717
Principal investigator 1 GlaxoSmithKline, LLC. $1,203.84 09/08/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809503667
Principal investigator 1 GlaxoSmithKline, LLC. $2,407.68 09/08/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809524699
Principal investigator 1 GlaxoSmithKline, LLC. $1,492.92 09/08/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809540917
Principal investigator 1 PFIZER INC. $18,509.70 09/04/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832907149
Principal investigator 1 GlaxoSmithKline, LLC. $1,461.24 09/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809497801
Principal investigator 1 PFIZER INC. $392.04 09/01/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832673491
Principal investigator 1 PFIZER INC. $48,658.50 08/21/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832907157
Principal investigator 1 GlaxoSmithKline, LLC. $9,585.18 08/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494725
Principal investigator 1 GlaxoSmithKline, LLC. $3,501.63 08/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494849
Principal investigator 1 GlaxoSmithKline, LLC. $965.25 08/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809521607
Principal investigator 1 GlaxoSmithKline, LLC. $3,501.63 08/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809497549
Principal investigator 1 PFIZER INC. $65,943.90 08/06/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832715947
Principal investigator 1 GlaxoSmithKline, LLC. $3,501.63 08/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809521717
Principal investigator 1 PFIZER INC. $3,498.00 07/31/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832674091
Principal investigator 1 GlaxoSmithKline, LLC. $579.15 07/27/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809521595
Principal investigator 1 GlaxoSmithKline, LLC. $4,080.78 07/27/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809521601
Principal investigator 1 PFIZER INC. $200.00 07/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832674109
Principal investigator 1 PFIZER INC. $11,356.50 07/21/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832917243
Principal investigator 1 GlaxoSmithKline, LLC. $4,569.84 07/20/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809525127
Principal investigator 1 PFIZER INC. $3,737.00 07/20/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832717287
Principal investigator 1 GlaxoSmithKline, LLC. $579.15 07/14/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809497543
Principal investigator 1 PFIZER INC. $3,614.16 07/14/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832673085
Principal investigator 1 GlaxoSmithKline, LLC. $3,829.32 07/07/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809497797
Principal investigator 1 PFIZER INC. $4,825.92 07/07/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832673103
Principal investigator 1 GlaxoSmithKline, LLC. $1,681.02 06/23/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809486975
Principal investigator 1 GlaxoSmithKline, LLC. $1,647.36 06/23/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490019
Principal investigator 1 PFIZER INC. $12,406.00 06/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832877863
Principal investigator 1 PFIZER INC. $4,678.08 06/16/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832673949
Principal investigator 1 PFIZER INC. $1,071.84 06/12/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832672511
Principal investigator 1 PFIZER INC. $7,683.72 06/11/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832672531
Principal investigator 1 GlaxoSmithKline, LLC. $386.10 06/09/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809497537
Principal investigator 1 GlaxoSmithKline, LLC. $1,988.91 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494695
Principal investigator 1 GlaxoSmithKline, LLC. $875.16 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494735
Principal investigator 1 GlaxoSmithKline, LLC. $1,351.35 06/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809521483
Principal investigator 1 PFIZER INC. $23,750.10 05/21/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832781445
Principal investigator 1 GlaxoSmithKline, LLC. $3,069.99 05/19/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809521477
Principal investigator 1 PFIZER INC. $1,790.00 05/12/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832818765
Principal investigator 1 PFIZER INC. $2,163.48 05/08/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832674099
Principal investigator 1 GlaxoSmithKline, LLC. $1,988.91 05/03/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809488883
Principal investigator 1 PFIZER INC. $3,102.00 04/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832917237
Principal investigator 1 GlaxoSmithKline, LLC. $1,255.32 04/21/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809487575
Principal investigator 1 GlaxoSmithKline, LLC. $2,779.92 04/21/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809488877
Principal investigator 1 GlaxoSmithKline, LLC. $1,988.91 04/21/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809490021
Principal investigator 1 PFIZER INC. $4,605.48 04/20/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832672521
Principal investigator 1 PFIZER INC. $11,979.00 04/09/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832791773
Principal investigator 1 GlaxoSmithKline, LLC. $1,396.89 03/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809487051
Principal investigator 1 GlaxoSmithKline, LLC. $1,673.10 03/24/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809488881
Principal investigator 1 PFIZER INC. $13,850.00 03/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 832673095
Principal investigator 1 PFIZER INC. $6,963.00 03/24/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832839901
Principal investigator 1 GlaxoSmithKline, LLC. $4,705.47 03/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809486973
Principal investigator 1 GlaxoSmithKline, LLC. $290.07 03/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809488879
Principal investigator 1 GlaxoSmithKline, LLC. $2,779.92 03/01/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809497449
Principal investigator 1 PFIZER INC. $63,409.50 02/23/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832854741
Principal investigator 1 GlaxoSmithKline, LLC. $1,203.84 02/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809494727
Principal investigator 1 GlaxoSmithKline, LLC. $6,000.00 02/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809497447
Principal investigator 1 GlaxoSmithKline, LLC. $4,300.00 02/17/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809521710
Principal investigator 1 GlaxoSmithKline, LLC. $10,504.89 02/10/2021 Non-covered Recipient Entity
MEDPHARMICS LLC
Not supplied No dispute reported 06/30/2026 809525121
Principal investigator 1 PFIZER INC. $19,156.50 02/05/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832865191
Principal investigator 1 PFIZER INC. $44,599.50 01/16/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832791763
Principal investigator 1 PFIZER INC. $37,461.60 01/09/2021 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832889733